Nothing To SAVOR For Bristol/AZ From Onglyza Results
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Bristol and AstraZeneca announced mixed results from a post-marketing study for their diabetes drug Onglyza that will likely have no commercial ramifications for the drug, which has been a disappointment since its launch in 2009.
You may also be interested in...
FDA Used Invokana Review To Reflect On Diabetes CV Risk Policy
Agency officials viewed the review of canagliflozin – the first program started after the 2008 outcomes trial requirement – as a chance to look at lessons learned since the policy went into effect.
FDA Used Invokana Review To Reflect On Diabetes CV Risk Policy
Agency officials viewed the review of canagliflozin – the first program started after the 2008 outcomes trial requirement – as a chance to look at lessons learned since the policy went into effect.
Merck And Pfizer Make A Late Play For The Diabetes Market
Two of the world’s largest pharmaceutical companies are teaming up to develop a treatment for type 2 diabetes, but the drug will have plenty of competitors with a better market position by the time it faces regulatory approval.